3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
2
Active not recruiting
2
Terminated
1
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
2
Conditions
Neoplasms
4
Hematologic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Lymphoproliferative Disorders
2
Glioma
2
Melanoma
1
Locally Advanced Thyroid Gland Carcinoma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Advanced Thyroid Cancer Patients Who Received Target Therapy
1
Interventions
pembrolizumab
47
Specimen Handling
29
Magnetic Resonance Spectroscopy
25
Biopsy
25
Radiosurgery
17
Gemcitabine
17
Nivolumab
15
Paclitaxel
14
Cyclophosphamide
13
Cisplatin
13
Carboplatin
13
Bevacizumab
12
Drug Therapy
11
Taxes
10
Radiotherapy
10
Oxaliplatin
10
Leucovorin
10
Irinotecan
10
Fluorouracil
10
Capecitabine
10
trastuzumab deruxtecan
8
fludarabine
8
Pemetrexed
8
Doxorubicin
8
Cetuximab
8
cemiplimab
7
abemaciclib
7
Trastuzumab
7
Fulvestrant
7
Docetaxel
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasm Metastasis
×
entrectinib
×
Clear all
NCT05525858
2025-04-27
KOSMOSII
Seoul National University Bundang Hospital
Recruiting
1,000 enrolled
NCT04817956
2024-02-29
IMPRESS-N
Oslo University Hospital
Phase 2
Recruiting
3,000 enrolled